Colon cancer represents a paradigm for the connection between inflammation and cancer in terms of epidemiology and mechanistic studies in preclinical models. Key components of cancer promoting inflammation include master transcription factors (for example, nuclear factor jB, STAT3), proinflammatory cytokines (for example, tumor necrosis factor, interleukin-6 (IL-6)), cyclooxygenase-2 and selected chemokines (for example, CCL2). Of no less importance are mediators that keep inflammation in check, including IL-10, transforming growth factorb, toll-like receptor and the IL-1 receptor inhibitor TIR8/ SIGIRR, and the chemokine decoy and scavenger receptor D6. Dissection of molecular pathways involved in colitis-associated cancer may offer opportunities for innovative therapeutic strategies.
Introduction: the link between inflammation and cancer
Tumors of the gastrointestinal tract provide a paradigmatic connection between inflammation and cancer. Even though colorectal cancer (CRC) does not always develop after a history of inflammatory bowel disease (IBD), a major building block of the current inflammation-and-cancer paradigm are epidemiological studies in colon cancer, including its high frequency in patients with IBD, the protective function of nonsteroidal antiinflammatory drugs and genetic associations with genes that encode inflammatory mediators. Moreover, preclinical models of colitis-associated cancer (CAC) have provided an invaluable tool to dissect the mechanistic basis of cancer-related inflammation.
Smoldering, nonresolving inflammation is part of the tumor microenvironment in gastrointestinal as well as other tumors (Balkwill and Mantovani, 2001; Coussens and Werb, 2002; Mantovani et al., 2008) . Inflammatory cells and mediators are present in the microenvironment of cancers epidemiologically related or unrelated to inflammatory or infectious conditions. Leukocyte infiltration and the presence of soluble mediators such as cytokines and chemokines, are key characteristics of cancer-related inflammation. Conditions predisposing to cancer (for example, IBD) or genetic events that cause neoplastic transformation orchestrate the construction of an inflammatory microenvironment. Indeed, alterations of genes representative of all classes of oncogenes drive the production of inflammatory mediators. Thus, an intrinsic pathway of inflammation (driven in tumor cells) as well as an extrinsic pathway driven by chronic inflammatory conditions have been identified, both of which contribute to tumor progression (Mantovani et al., 2008) . Cancer-related inflammation has therefore emerged as the seventh hallmark of cancer (Mantovani, 2009) .
The relationship between IBD and CRC
Crohn's disease (CD) and ulcerative colitis (UC) are the two main forms of IBD. Because of chronic damage to the colon and rectum, both types of IBD are at increased risk of developing CRC. CAC only accounts for B2% of all the cases of CRC (Gyde et al., 1982; Choi and Zelig, 1994) ; however, there is an incidence rate of B2.75 and 2.64 in patients with UC and CD, respectively (Bernstein et al., 2001) . These studies went on to identify the major factors involved in the development of CAC in patients with IBD, such as the severity and extension of disease and duration of inflammation. Indeed, the risk of developing CAC increases by B0.5-1% after 10 years of chronic inflammation, with a cumulative probability of 18% after colonic disease of 30 years duration (Eaden et al., 2001) .
Colitis-associated cancer occurs when normal cell growth and tissue homeostasis is disrupted by sequential mutations and epigenetic alterations of cancer-related genes, with DNA methylation, histone modification and mutations mediated through the reactive oxygen species released by innate immune cells (Kundu and Surh, 2008; Colotta et al., 2009) . Indeed, oxidative stress has been linked to several cancer-prone mutations in intestinal epithelial cells including p53, Bcl-2, adenomatous polyposis coli (APC) and p16 (reviewed by Roessner et al., 2008) . This disrupts key processes, resulting in the malignant transformation of cancer stem cells. Recently, the focus has been on the inflammatory cells and circuits that are active in the tumor microenvironment, as it is now becoming clear that they also have a crucial role in the development and progression of tumors (Balkwill and Mantovani, 2001; Coussens and Werb, 2002; Balkwill et al., 2005; Karin, 2006; Mantovani et al., 2008) .
The pathophysiology of CAC
Several molecules have emerged as key players in the link between IBD and CAC. In particular, a variety of inflammatory mediators have a more specific role in the initiation and development of CAC. Until recently, very little data was available on the link between intestinal inflammation and colon cancer. However, the development of new animal models has opened up avenues on key molecules involved in the progression from colonic inflammation to cancer.
Several experimental models of colonic cancer have been developed, including the APCmin and the azoxymethane (AOM) model. The latter represents a very valuable rodent model for the study of CAC, because it is a variation on a standard UC model in which mice are administered dextran sulfate sodium (DSS) orally to induce colitis (Okayasu et al., 1990) . Repeated oral ingestion of DSS can cause colon carcinoma (Okayasu et al., 2002) ; however, the effect is enhanced by administration of AOM before the first administration of DSS, which causes formation of O-6-methylguanine and consistently promotes the development of colon carcinoma (Okayasu et al., 1996) (Figures 1 and 2 ). Although none of the models faithfully recapitulate the pathogenesis and diversity of human colon cancer, they have been invaluable in shedding fresh new light on CAC.
Molecules that have been implicated in the development of colon carcinoma include positive regulators such as the proinflammatory cytokines tumor necrosis factor-a (TNFa), interleukin-1 (IL-1), IL-6 and proinflammatory CC-chemokines; negative regulators such as transforming growth factor-b (TGFb), IL-10, TIR8 (also known as single immunoglobulin IL-1R-related molecule, SIGIRR), decoy receptor D6, cyclooxygenase-2 (COX-2) as well as innate immunity receptors and signaling molecules such as toll-like receptor 4 (TLR4), MyD88; and the master transcription factor nuclear factor kB (NF-kB) (Figure 3 ).
Immune cells in CAC
Colitis-associated cancer is characterized by a dense infiltrate of immune cells, including macrophages, dendritic cells and T cells, which include the subset of CD8 þ and CD4 þ (T-bet þ ) effector T cells and CD4 þ CD25 þ T cells (Waldner et al., 2006) . However, the functional role of these immune cells is only recently beginning to be unveiled. Recently, Garrett et al. (2009) identified that DCs were the necessary cellular effectors for the proinflammatory carcinogenic program of their T-Bet(À/À) RAG2(À/À) UC model, elegantly showing that targeted restoration of T-bet in DC could reduce colonic inflammation and prevent the development of spontaneous neoplasia. In a novel model of IBD and CAC using genetic inactivation of STAT3 in macrophages, Deng et al. (2010) . showed that inflammation was associated with activation of the mTOR-STAT3 pathway in epithelial and tumor cells, which was essential for both the excess proliferation of these cells and the disruption of colonic homeostasis in mutant mice.
Toll-like receptors
Toll-like receptors have a major role in sensing gut microbiota, and activation of these receptors is required to maintain intestinal homeostasis that is often disturbed in IBD. Polymorphisms in TLR4 have been associated with UC and CD (Fukata and Abreu, 2008) . TLR4 is upregulated in intestinal epithelial cells in active CD and UC (Cario and Podolsky, 2000) , and its signaling induces COX-2, prostaglandin E2 and reactive oxygen species (Fukata and Abreu, 2008) .
Evidence is mounting to support a role for TLRs in carcinogenesis. It was shown that a deficiency in the TLR adaptor, MyD88, significantly reduced tumor number and size in the Apcmin/ þ mouse model of intestinal tumorigenesis (Rakoff-Nahoum and Medzhitov, 2007) . Furthermore, the absence of bacteria in several mouse models of inflammation-associated cancer has resulted in abrogation of dysplasia or cancer (Fukata and Abreu, 2008) . Thus, the presence and recognition of a b c d Figure 1 Colitis-associated cancer. Endoscopic view of murine healthy intestine (a) and after 7 days of 3% DSS treatment with colitis establishment (b). Treatment with three weekly cycles of 3% DSS and AOM leads to colitis-associated cancer (c, d).
A paradigm of the Yin-Yang interplay between inflammation and cancer S Danese and A Mantovani bacteria in the gut seems to be necessary for inflammation-associated carcinogenesis. In the gut, mice inoculated with colon cancer cells silenced for expression of TLR4 showed increased survival and a significant reduction in tumor size compared with mice injected with cells expressing control short interfering RNA (Huang et al., 2005) . Furthermore, using the AOM-DSS mouse model of CRC, it was shown that TLR4-deficient mice exhibited significantly reduced tumor number and size compared with wild-type controls (Fukata et al., 2007) . In general, a close link between innate and adaptive immunity, inflammation and carcinogenesis is well established in many forms of cancer, including CAC. Indeed, pattern recognition receptors such as TLR and NLR are key components of the 'danger model' proposed by Rakoff-Nahoum and Medzhitov (2009) . They have a critical role in the recognition of microbespecific molecules (pathogen-associated molecular patterns, PAMPs) or endogenous stress signals (damage-associated molecular pattern, DAMPs) and the subsequent birth of a more or less effective or beneficial immune response. One of the DAMPs, the nuclear HMGB1 protein, has been associated with the proliferation and metastasis of many tumor types. Very recently, the clinical efficacy of some chemotherapeutic agents, such as oxaliplatin, has been related to TLR4 expression. Indeed, it has been shown that patients carrying the TLR4 loss-of-function allele exhibited reduced progression-free and overall survival, as compared with patients carrying the normal TLR4 allele, when treated with oxaliplatin. These data suggest that inflammation can act as a double-edged sword in clinical cancer and that further studies are needed to dissect the interplay between innate and adaptive immunity (Tesniere et al., 2010) .
Cytokines
TNFa. Tumor necrosis factor-a is a key regulator of inflammation that binds to and activates its receptor (TNFR), inducing the recruitment of intracellular adaptor proteins. The TNFR can trigger NF-kB and downstream cell survival pathways or it can trigger caspase 8 and associated apoptotic pathways (Balkwill, 2006) .
Mice deficient for TNFa or its receptor, TNFR, are resistant to skin carcinogenesis, which directly supports the concept that TNFa promotes tumorigenesis (Moore et al., 1999; Arnott et al., 2004) . Expression of TNFa was also increased in gastric lesions and inflamed colonic mucosa of patients with IBD (Noach et al., 1994; Noguchi et al., 1998) . However, reports on the role of TNFa have been conflicting, potentially acting as A paradigm of the Yin-Yang interplay between inflammation and cancer S Danese and A Mantovani either a tumor-promoting or tumor-destructive factor (Szlosarek et al., 2006) . At high doses, hemorrhagic tumor necrosis occurs through selective destruction of tumor blood vessels and activation of T cells that attack and eliminate tumor cells. However, the levels of TNFa required for this activity can be extremely toxic. However, at the low doses seen during chronic production, expression of TNFa is observed in several tumor types and is important in the promotion of all stages of cancer development, that is, from growth to invasion and metastasis. Indeed, several clinical studies provide evidence that TNFa contributes to the development of human cancers, including CRC. TNFa is found in the microenvironment of many types of tumor, including breast, ovarian, colorectal, prostate, melanoma, lymphomas and leukemia (Szlosarek and Balkwill, 2003; Balkwill, 2009 ) Specifically, in CRC, the mRNA and protein levels of TNFa are increased to abnormal levels in the preneoplastic inflamed colonic mucosa (Noguchi et al., 1998) .
The role of the signaling pathways downstream of TNFa was explored in mice deficient in the type 1 TNF receptor, p55 (Popivanova et al., 2008) . In the absence of TNFa signaling, there was decreased mucosal damage, inflammatory cell infiltrates and cytokine expression in the mucosa, in response to the AOM challenge and DSS, as well as a significant reduction in tumor formation. Wild-type mice were administered the specific TNFa antagonist etanercept in the AOM challenge model. In these mice, neutrophil and macrophage infiltration into the mucosa was decreased, as was tumor number and size. Although etanercept is currently used for the treatment of rheumatoid arthritis, it showed insufficient efficacy compared with anti-TNFa monoclonal antibodies for the treatment of IBD. Nonetheless, these data point to the possibility that monoclonal antibodies directed against TNFa could have a similar ability to inhibit tumor formation in these patients (Burstein and Fearon, 2008) . Patients who have been exposed to anti-TNF antibodies were determined to be at increased risk of developing cancers, in a study that included patients who developed colon cancer (Bongartz et al., 2006) . However, no safety concerns regarding the incidence of IBD-associated colon carcinoma were identified in a recent study of patients who were administered infliximab (Biancone et al., 2009 ).
IL-6. Interleukin-6 is considered to be an important player in the transition between acute and chronic Inflammation, as well as between innate and acquired immunity, especially in intestinal inflammation (Hoebe et al., 2004; Jones, 2005) . It modulates chemokine and adhesion molecule expression and apoptosis, suppressing neutrophil infiltration and promoting the accumulation of mononuclear leukocytes, which directs the A paradigm of the Yin-Yang interplay between inflammation and cancer S Danese and A Mantovani resolution of acute inflammation and the activation of acquired immunity (Hurst et al., 2001; McLoughlin et al., 2003; Mantovani et al., 2005) . Evidence that IL-6 has such a role came from the demonstration that inhibition of IL-6 signaling affected chemotaxis and apoptosis of lamina propria mononuclear cells, improving disease outcome in animal models of colitis (Atreya et al., 2000; McLoughlin et al., 2003) . In clinical studies, high levels of IL-6 and a soluble form of the IL-6 receptor were shown in the peripheral blood of patients with IBD, in which it promotes accumulation of T cells in the lamina propria of the colon by upregulating antiapoptotic factors, including Bcl-2 and Bcl-xl (Atreya et al., 2000; McLoughlin et al., 2003) . IL-6 has also been shown to have an important role in the generation of TH17, the main pathogenic cells in CD (Mangan et al., 2006; Bettelli et al., 2006) . In human cancers, increased IL-6 levels have been observed in both the serum of cancer patients and in tumor biopsies (Chung and Chang, 2003; Kai et al., 2005) . The role of IL-6 has subsequently been explored in genetically manipulated loss-of-function and gain-offunction mice Grivennikov et al., 2009) . Both loss-of-function and gain-of-function mice underwent the AOM challenge protocol. After induction of colitis, it was shown that IL-6, which was mainly produced by lamina propria myeloid cells, promoted proliferation and survival of premalignant intestinal epithelial cells, thus enhancing both initiation and progression of CAC Grivennikov et al., 2009) . The AOM experimental model was also used to directly address whether IL-6 has a role in the development of colon cancer. In the mouse AOM challenge model, tumor growth was dependent on the IL-6 from the inflamed tissues, whereas blockade of IL-6 signaling dramatically reduced the size and number of tumors in these mice (Becker et al., 2004) . On the other hand, deletion of suppressor of cytokine signaling 3, which limits the ability of IL-6 to activate transcription, results in mice with increased susceptibility to AOM/ DSS-induced tumors (Rigby et al., 2007) .
Finally, Li et al. (2010) investigated the expression of IL-6 and its epithelial targets in patients with UC who had progressed to CRC. They found that the expression of both IL-6 and STAT3 was greater in both patients with active UC and those who had progressed to CAC, compared with both patients with inactive disease and control patients. On the other hand, the expression of suppressor of cytokine signaling 3 was increased in patients with either inactive or active UC, compared with control individuals, but was decreased in patients with UC who had progressed to CRC. These data indicate that IL-6 and STAT3 have an important role in CAC, whereas loss of suppressor of cytokine signaling 3 is important to its progression .
Chemokines
Chemokines are a superfamily of small secretory proteins that mediate the directional migration of both hematopoietic and nonhematopoietic cells (Rollins, 1997; Luster, 1998; Mantovani, 1999) . Their biological functions include diverse activities such as leukocyte recruitment to sites of infection or inflammation, tumor metastasis, tissue patterning during development and human immunodeficiency virus-1 infection (Kelvin et al., 1993; Murphy, 1994; Murphy et al., 2000) . Beside the conventional signaling receptors, 'decoy' chemokinebinding proteins with structural similarity with conventional receptors but lacking signaling function, that is, decoy receptors, have been described (D'Amico et al., 2000; Mantovani et al., 2001) . Essential attributes for the decoy receptors include loss of signaling function and the desensitization response, while retaining highaffinity ligand binding.
The atypical chemokine receptor D6, a decoy and scavenger receptor that is mainly expressed on nonhematopoietic cells, such as endothelial cells lining afferent lymphatics in skin and lung (Nibbs et al., 2001 ) and trophoblasts in the placenta (Nibbs et al., 1997) D6 knock-out mice develop more severe colitis, which is associated with an increased production of chemokines and inflammatory cell recruitment (Vetrano et al., 2009 ). When cancer is chemically induced in the D6 knock-out mice, D6 absence in the nonhematopoietic compartment leads to increased susceptibility of inflammation and malignancy development. Finally, the expression is increased in the lymphatic vascular bed of colonic sections from humans with IBD compared with that in healthy humans, and this increase is even more marked in patients who have developed colon cancer associated with IBD. These results point to a novel and previously unknown role of D6 in the control of intestinal inflammation and inflammation-associated colon cancer through the lymphatic system.
Tumor necrosis factor-a induces expression of chemokines from a variety of colonic cells such as epithelial cells, fibroblasts, endothelial cells and leukocytes (Wang et al., 2003) , thereby having an indirect chemotactic effect on macrophages and granulocytes. Indeed, the mucosa of patients with IBD exhibited enhanced mRNA and protein expression of MCP-1/CCL2 (Reinecker et al., 1995; Mazzucchelli et al., 1996; Uguccioni et al., 1999) , a CC-chemokine with potent chemotactic and activating activities for monocytes/ macrophages (Matsushima et al., 1989) . They observed that CCL2 mRNA expression was enhanced in the colon of the AOM challenged mouse model, and that blocking the TNFa/TNFR axis reduced colorectal carcinogenesis, intracolonic macrophage infiltration and CCL2 mRNA expression (Popivanova et al., 2008) . These observations prompted investigation of the roles of CCL2 and its specific receptor, CCR2, in the AOM challenged mouse model. In the presence of CCL2-blocking agents, the expression of CCL2 was enhanced, together with intracolonic massive infiltration of macrophages, which were a major source of COX-2. Mice deficient in CCR2 exhibited less macrophage infiltration and lower tumor numbers with attenuated COX-2 expression. Moreover, CCL2 antagonists decreased intracolonic macrophage infiltration and COX-2 expression, attenuated neovascularization and eventually reduced the numbers and size of colon tumors, even when given after multiple colon tumors had developed. These observations identify CCL2 as a crucial mediator of the initiation and progression of chronic colitis-associated colon carcinogenesis and suggest that targeting CCL2 may be useful in treating colon cancers, particularly those associated with chronic inflammation (Popivanova et al., 2009) .
In addition to the mechanistic studies that have addressed the direct role of chemokines in CAC, it is also worth mentioning that chemokines are involved in a variety of functions, including angiogenesis. As angiogenesis is an essential step in the tissue damage and remodeling associated with IBD, and this is dependent on several chemokines, it is likely that chemokines could also have a role in CAC by promoting and maintaining the pathological angiogenesis present in intestinal tumors.
Negative regulators IL-10. Interleukin-10 is a key mediator in the pathogenesis of IBD. It has long been established that mice genetically deficient for IL-10 develop spontaneous enterocolitis (Kuhn et al., 1993) . Very recently, Glocker et al. (2009) showed that patients with mutations in the IL-10 receptors that abrogate IL-10 signaling develop early and aggressive disease. IL-10 knock-out mice go on to develop CAC through a mechanism that has been associated with aberrant Th1 cytokine production (Berg et al., 1996) . In particular, the demonstration that IL-10 suppresses IL-6 and controls CAC development in a model of microbial CRC indicates that control of CAC development by IL-10 may be at least partially mediated through IL-6. Taken together, these data reinforce the notion that IL-10 is a key mediator for intestinal immune homeostasis, and suggest that IL-10-dependent inflammation influences IL-6-driven CAC development.
Transforming growth factor-b
Transforming growth factor-b has long been implicated in the pathogenesis of sporadic CAC. However, the mechanism underlying its involvement has only recently been elucidated. In an elegant set of experiments, Becker et al. (2006) investigated the functional role of TGFb using the AOM model with TGFb receptor-deficient and TGFb transgenic mice. The authors reported that the TGFb receptor-deficient mice developed a significantly higher number of tumors than wild-type mice, whereas the opposite occurred in the TGFb transgenic mice. In mechanistic studies, the authors found that, similar to IL-10, TGFb also inhibited IL-6-dependent tumor formation, thus reinforcing the concept that immunoregulatory molecules, such as IL-10 and TGFb, have a protective effect on intestinal inflammation and in CAC formation (Becker et al., 2006) .
Complementary data were obtained by Fantini et al. (2009) , who generated mice transgenic for the TGFb inhibitor smad7, with overexpression specifically on T cells. Although these mice developed a greater severity of colitis in response to the AOM/DSS challenge, the mice only developed few, small tumors compared with the many large tumors that developed in wild-type mice. Interestingly, high expression of IFNg, IL-6 and IL-17 were found in the tumor-free areas of the smad7 transgenic mice, indicating a potential for IFNg in antitumor responses in the gut. However, this is in contrast to work by Osawa et al. (2006) . In a variation on the standard AOM model, involving induction of colitis with trinitrobenzene sulfonic acid after the initial administration of AOM, Osawa and colleagues showed that mice genetically deficient for IFNg develop significantly fewer tumors compared with either wild-type mice or with IL-4-deficient mice. These conflicting reports indicate the complexity of the underlying mechanisms.
TIR8. Signaling by TLRs and IL-1 receptors is controlled by negative regulatory pathways (Brint et al., 2004; Mantovani et al., 2004) . A recently identified orphan member of the IL-1 receptor family, TIR8, inhibits signaling from IL-1R/TLR complexes, possibly by trapping interleukin-1 receptor-associated kinase-1 and TNF receptor-associated factor-6 ( Thomassen et al., 1999; Polentarutti et al., 2003; Wald et al., 2003; Mantovani et al., 2004) . TIR8 gene transfer experiments have revealed that it reduces activation of NF-kB by the IL-1R complex (Polentarutti et al., 2003) , as well as by members of the TLR family (Wald et al., 2003; Garlanda et al., 2009) .
TIR8, also named SIGIRR, is expressed in several tissues, especially in the epithelial cells of the digestive tract (Polentarutti et al., 2003) . Accordingly, there is evidence for a nonredundant regulatory role of this molecule in inflammation involving the gastrointestinal mucosa (Garlanda et al., , 2007 Xiao et al., 2007) . Tir8-deficient mice administered DSS exhibited dramatic weight loss, intestinal bleeding and mortality, whereas the susceptibility to CAC in the AOM challenge model was increased. An important end point of TLR signaling is NF-kB activation, and aberrant TLR signaling may contribute to the tumor-promoting activity of NF-kB. Interestingly, prostaglandin E2, proinflammatory cytokines (IL-1 and IL-6) and chemokines (KC/CXC, JE/CCL2 and CCL3) are present downstream of NF-kB. The lack of a checkpoint (TIR8) of NF-kB activation leads to increased carcinogenesis in the gastrointestinal tract. Thus, specific TLR pathways may provide new targets for therapies to interrupt oncogenic pathways associated with IBD.
COX-2. Cyclooxygenase-2 is a cytoplasmic protein that catalyzes the synthesis of lipid inflammatory
A paradigm of the Yin-Yang interplay between inflammation and cancer S Danese and A Mantovani mediators (prostaglandins and prostacyclins) from arachidonic acid. Expression is increased at the sites of inflammation (Herschman et al., 1995) , as well as in B80% of CRCs and 40% of colorectal adenomas (Eberhart et al., 1994) . Indeed, the COX-2 protein is found in the cytoplasm of neoplastic colonic epithelial cells and to a lesser extent in stromal cells, whereas normal epithelium is negative for COX-2 (Sinicrope and Gill, 2004) . Finally, the expression of COX-2 is also upregulated in neoplastic cells in mice with mutations in the tumor suppressor Apc, after the AOM/DSS challenge (Sinicrope and Gill, 2004) . The fact that COX-2 is important in the development of CAC is further supported by the demonstration that nonsteroidal antiinflammatory drugs that specifically target COX-2 (coxibs) can reduce both the incidence of colon cancer and mortality rate in rodent models and humans (Jacoby et al., 2000; Oshima et al., 2001) . COX-2 may contribute to tumor development by modulating apoptosis, angiogenesis and tumor invasiveness, as overexpression of COX-2 in rat intestinal epithelial cells had increased adherence to the extracellular matrix, resistance to apoptosis-inducing agents and upregulation of the antiapoptotic protein B-cell lymphoma-2 (Bcl-2) (Tsujii and DuBois, 1995) . Similar results were obtained when COX-2 was overexpressed in human colon cancer cells, with COX-2 providing resistance to apoptosis after treatment with antineoplastic drugs (Sun et al., 2002) .
Cyclooxygenase-2 also has a role in the progression of cancer, by activating metalloprotease, matrix metalloproteinase-2, and thereby increasing the invasiveness of colon cancer cells (Li et al., 2002) . Furthermore, suppression of COX-2 in human prostate tumor cells by a selective COX-2 inhibitor resulted in reduced levels of matrix metalloproteinase-2 and matrix metalloproteinase-9 (Attiga et al., 2000) . As COX-2 has an extensive role in inflammation and various aspects of carcinogenesis, it is an attractive target for therapeutic intervention in inflammatory disorders and cancer. A search for COX-2-specific inhibitors resulted in promising candidates, such as valdecoxib, celecoxib and rofecoxib. However, although the chemopreventive action of these drugs is promising, the effects of COX-2 inhibitors in IBD is deleterious, as these drugs have negative effects on intestinal inflammation, by worsening the disease (Matuk et al., 2004) .
NF-kB. Activation of NF-kB is associated with various types of cancers, including colon cancer, which is not surprising given its key role in innate immunity, inflammation and cell proliferation and survival (Naugler and Karin, 2008) . It also controls the expression of inflammatory cytokines, adhesion molecules, enzymes in the prostaglandin synthesis pathway (including COX-2), inducible nitric oxide synthase and a number of antiapoptotic genes, including Bcl-2, thus providing a survival advantage to tumor cells (Mantovani et al., 2008) .
Nuclear factor kB is activated by signaling pathways mediated through TLRs and other microorganismsensing molecules, or by TNFa and IL-1b (Mantovani et al., 2008) . Regulation of NF-kB involves sequestration of NF-kB in the cytoplasm by the inhibitor kB, which is in turn regulated through phosphorylation by the inhibitor kB kinase (IKK) complex, targeting it for ubiquitindependent degradation (Greten and Karin, 2004; Bollrath and Greten, 2009 ). Degradation of inhibitor kB releases NF-kB, allowing it to translocate to the nucleus, wherein it mediates transcription of downstream targets that can be separated into four functional categories: antiapoptotic genes, inflammatory and immunoregulatory genes, genes that promote cell-cycle progression and genes that encode negative regulators of NF-kB. Many of these targets have been associated with cancer initiation and progression (Greten and Karin, 2004) . showed that IKKb links inflammation and tumorigenesis in a mouse model of CAC, in which IKKb was deleted either in intestinal epithelial cells or in the myeloid cells. CRC was induced in these two different mouse models, with AOM and DSS. When NFkB activity was disrupted in colonic epithelial cells, there was a dramatic reduction in tumor number in these mice. This was associated with enhanced epithelial cell apoptosis during early tumor development, whereas there was no reduction in inflammation. Thus, the authors concluded that activation of NF-kB in epithelial cells contributes to tumor initiation and promotion, primarily by suppressing apoptosis. In mice with IKKb deleted in the myeloid cells, there was reduced expression of many genes involved in inflammatory responses, including IL-1b, IL-6, macrophage inflammatory protein 2, TNFa, COX-2 and intercellular adhesion molecule . These mice exhibited a significant reduction in tumor size and some reduction in tumor number. From these results, the authors suggest that myeloid cells contribute to tumor development through production of paracrine signaling molecules that promote tumor growth. NF-kB has also been shown to induce vascular endothelial growth factor and COX-2, which promote angiogenesis (Greten and Karin, 2004) .
The role of NFkB in the homeostasis of the epithelial barrier homeostasis and in the response to microbes and inflammatory signals is complex (Pasparakis, 2008) . It therefore remains to be established whether it represents a valuable target for the prevention and treatment of CAC.
Conclusions and implications for therapy and prophylaxis
Colon cancer has provided a paradigm for the connection between inflammation and cancer. However, key questions remain open. There is strong evidence showing that T-cell infiltration, presumably a manifestation of effective adaptive immunity, is a favorable prognostic element in colon cancer (Laghi et al., 2009) . Whether and to what extent that applies to the tumors epidemiologically related to colitis remains to be defined. At a more fundamental level, activation and orientation of adaptive responses depends on innate immunity. In other clinical settings, chemotherapyinduced cell death can activate protective innate responses (Apetoh et al., 2007) . Thus, the Yin-Yang balance of innate immunity and inflammation in colon cancer and in CAC remains to be dissected.
Both association and mechanistic studies provide a clear link between the chronic inflammation found in patients with IBD and the development of CAC. However, our knowledge of the molecules involved in the initiation of CAC in IBD is very much in its infancy. Interestingly, some drugs routinely used for the treatment of patients have been shown to reduce the risk of CAC.
For instance, in recent years a large amount of molecular data has accumulated supporting the notion that the biological effects of 5-aminosalicylic acid (5-ASA) interfere with the development of CRC. 5-ASA reduces oxidative stress, inhibits cell proliferation and promotes apoptosis (Gasche, 2004; Stolfi et al., 2008b) . At the molecular level, 5-ASA inhibits COX-2 (Peskar et al., 1987; Stolfi et al., 2008a) , decreases transcriptional activity of NF-kB by modulating phosphorylation of RelA/p65 and interferes with Wnt pathway through protein phosphatase 2A (Egan et al., 1999; Bos et al., 2006) . In addition to the therapeutic utility of 5-ASA for the prevention of CAC, the ongoing clarification of the molecular targets of 5-ASA will therefore likely provide novel targets for the development of chemopreventive compounds.
In addition, azathioprine was very recently reported to significantly decrease the risk of colon cancer in patients with IBD (Beaugerie et al., 2009) . Even though the mechanism is unclear, a possible explanation could be the simple reduction of mucosal inflammation and the induction of mucosal healing. Overall, although there is some utility of the therapeutics already used for the treatment of IBD, the ongoing elucidation of the molecules that are involved in the development of CAC is an important step toward identifying new targets for therapeutic intervention.
Beside TNFa, a number of other inflammatory cytokines and adhesion molecules are being targeted as potential therapies for IBD (Nakamura et al., 2006) , and these may also be efficacious for the prevention and treatment of CAC. Therapies in clinical trials include antibodies against the p40 subunit of IL-12/IL-23 and the IL-6 receptor. In addition, adhesion molecules that promote trafficking of leukocytes into the inflamed gut wall, such as a4-integrins, vascular cellular adhesion molecule 1 and intercellular adhesion molecule-1 are being targeted with antibodies and oligodeoxynucleotides. The challenge of these strategies is to identify therapies that can reduce aberrant inflammatory responses while retaining proper defenses against infection and functional tumor surveillance mechanisms.
